

Document downloaded from the institutional repository of the University of Alcalá: <http://dspace.uah.es/>

This is a postprint version of the following published document:

Sánchez-Nieves Fernández, J., Fransen, P., Pulido, D., Llorente Heras, R., Muñoz-Fernández, M.A., Albericio, F., Royo, M., Gómez Ramírez, R. & Mata De La Mata, Francisco J. De La 2014, "Amphiphilic Cationic Carbosilane-PEG Dendrimers: Synthesis and Applications in Gene Therapy", European Journal of Medicinal Chemistry, vol. 76, pp. 43-52.

Available at <http://dx.doi.org/10.1016/j.ejmech.2014.01.061>

© 2014 Elsevier

(Article begins on next page)



This work is licensed under a

Creative Commons Attribution-NonCommercial-NoDerivatives
4.0 International License.

Amphiphilic Cationic Carbosilane-PEG Dendrimers: Synthesis and Applications in Gene Therapy

Javier Sánchez-Nieves,^{a,b} Peter Fransen,^c Daniel Pulido,^{b,d} Raquel Lorente,^e M. Ángeles Muñoz-Fernández,^{b,e} Fernando Albericio,^{b,c,f,} Miriam Royo,^{b,d,*} Rafael Gómez^{a,b,*} and F. Javier de la Mata^{a,b,*}*

Cationic amphiphilic dendrimers

^a Department of Química Orgánica y Química Inorgánica, Universidad de Alcalá, Campus Universitario, E-28871 Alcalá de Henares (Madrid) Spain. FAX: 00 34 91 885 4683; Phone: 00 34 91 885 4685.

^b Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN).

^c Institute for Research in Biomedicine, Barcelona Science Park, Baldiri Reixac 10, 08028 Barcelona, Spain.

^d Combinatorial Chemistry Unit, Barcelona Science Park, Baldiri Reixac 10, 08028 Barcelona, Spain

^e Laboratorio de Inmunología Molecular, Hospital General Universitario Gregorio Marañón, Madrid (Spain).

^f Department of Organic Chemistry, University of Barcelona, Martí i Franqués 1-11, 08028 Barcelona, Spain

Abstract

Here we synthesized carbosilane, generation 1 to 3, and PEG-based dendrons functionalized at the periphery with NHBoc groups and at the focal point with azide and alkyne moieties, respectively. The coupling of these two types of dendrons via click chemistry led to the formation of new hybrid dendrimers with two distinct moieties, the hydrophobic carbosilane and the hydrophilic PEG-based dendron. The protected dendrimers were transformed into cationic ammonium dendrimers. These unique amphiphilic dendrimers were studied as vectors for gene therapy against HIV in peripheral blood mononuclear cells (PBMC) and their performance was compared with that of a PEG-free carbosilane dendrimer. The presence of the PEG moiety afforded lower toxicities and evidenced a weaker interaction between dendrimers and siRNA when compared to the homodendrimer analog. Both features, lower toxicity and lower dendriplex strength, are key properties for use of these vectors as carriers of nucleic material.

1. Introduction

In recent years, interest in treating diseases by gene therapy has grown as consequence of increased knowledge about the molecular pathways of diseases and the human genome. Gene therapy involves guiding functional genetic material, such as plasmids, nucleic acids (DNA and RNA) and oligonucleotides, to target cells.¹ Two types of gene delivery vectors can be distinguished, namely viral and non-viral. As a result of the intrinsic nature of viruses, the former have proved to be highly efficient, although they also show considerable disadvantages.^{2,3} The second type are based on synthetic vectors, such as macromolecules, polymers and nanosystems, which can be rationally designed according to needs.⁴⁻¹¹ These vectors are required to interact with nucleic acids, usually forming electrostatic complexes, compacting them and preventing their degradation. Thus, various systems functionalized with cationic groups have been used for this purpose.¹²


In the particular case of dendritic macromolecules, their characteristics, such as a well-defined size and structure, flexibility, monodispersity and multivalent molecular surface¹³⁻²², have attracted attention for biomedical applications. In this regard, several types of cationic dendrimers containing different skeletons have been explored for gene therapy.^{6,10,23-31} One such type comprises carbosilane dendrimers. Although these molecules are highly hydrophobic, water-soluble cationic carbosilane dendrimers have proved useful as non-viral vectors for gene therapy.³²⁻³⁶ Their strong amphiphilic behavior differentiates them from other kinds of dendrimers with a more hydrophilic skeleton. These molecules are able to bind oligonucleotides and siRNA and transport them to the interior of a range of cell types.³²⁻³⁶ In addition, these dendrimers protect nucleic material from degradation by serum proteins and nucleases. This protective feature is of fundamental importance as it ensures that nucleic material can exert an effect once inside the cell.³⁴ However, the major drawback of cationic dendrimers is their intrinsic toxicity. A strategy developed elsewhere to overcome this problem has been the binding of PEG moieties, an approach that also increases the solubility of the macromolecule.³⁷⁻⁴⁴

Taking these previous results into account, here we report the design and synthesis of Janus-type amphiphilic dendrimers composed of two types of dendrons, one based on the carbosilane moiety and the other on a PEG scaffold, both decorated with ammonium groups at their periphery. The synthesis of these dendrimers was performed by click chemistry (CuCAAC) using azide and alkyne groups at the focal point of carbosilane and PEG-based dendrons, respectively. Due to this composition, it is expected that these dendrimers increase their biocompatibility compared to carbosilane homodendrimers. This feature, along with complex formation with siRNA, cellular uptake, and HIV inhibition, was studied in primary peripheral blood mononuclear cells (PBMC).

2. Results and Discussion

2.1. Synthesis of dendrons and Janus-type dendrimers. For the synthesis of carbosilane dendrons, as precursors we chose dendrons with a C-Br bond at the focal point and Si-H groups at the periphery.⁴⁵ We have previously reported the synthesis of carbosilane homodendrimers functionalized with amine -NH₂ groups at the periphery by hydrosilylation of allylamine with SiH-terminated dendrimers.^{35,45} However, due to the chemical incompatibility of primary amine groups and C-Br bonds, this procedure is not adequate to obtain the dendrons required for preparation of the Janus-type dendrimers objective of this study. Therefore protection of the amine groups with Boc was necessary in order to use the same synthetic procedure. Thus, the reaction of Boc-protected allylamine C₃H₅NHBoc with 1-3 generation dendrons BrG_n(SiH)_m (n = 1, m = 2; n = 2, m = 4; n = 3, m = 8) (Scheme 1) afforded the corresponding dendrons BrG_n(NHBoc)_m (n = 1, m = 2 (**1**); n = 2, m = 4 (**2**); n = 3, m = 8 (**3**)) in moderate yields (*ca.* 65 %). The reaction was followed by NMR spectroscopy, which showed the disappearance of the doublet corresponding to the methyl groups and the multiplet of the hydrogen atom of SiMe₂H moieties. **NMR spectroscopy also confirmed formation of these compounds (Figures S3-S4 in supporting information).** The new chain -Si(CH₂)₃NH- introduced in dendrons **1-3** was clearly identified by ¹H-¹H TOCSY NMR spectra, which showed four resonances at about δ 4.55, 3.05, 1.25 and 0.45. ¹³C NMR spectra presented one resonance at δ *ca.* 44.0 for the C-N atom of this chain and finally ²⁹Si NMR spectroscopy showed one


resonance for the new outer SiMe₂ group δ *ca.* 2.0. The bromine atom at the focal point of compounds **1-3** was easily replaced by an azide function through the reaction with NaN₃ (Scheme 1), thus obtaining the dendrons N₃G_n(NHBoc)_m ($n = 1, m = 2$ (**4**); $n = 2, m = 4$ (**5**); $n = 3, m = 8$ (**6**)) in high yield (*ca.* 85 %). The introduction of this group was confirmed by NMR spectroscopy (Figures S5-S8 in supporting information), which showed one resonance at δ *ca.* 3.25 in the ¹H NMR spectra and other resonance at δ *ca.* 51.0 in the ¹³C NMR spectra for the new N₃CH₂ methylene group.



Scheme 1. Synthesis of generation 1-3 carbosilane dendrons N₃G_n(NHBoc)_m ($n = 1, m = 2$ (**4**); $n = 2, m = 4$ (**5**); $n = 3, m = 8$ (**6**)). i) C₃H₅NHBoc, Pt Kardstedt's catalyst, THF, 60 °C, 12 h; ii) NaN₃, DMF, NaI, 80 °C, 12 h.


The alkyne PEG-based dendron consisted of a branching unit derived from diethylenetriaminepentaacetic acid (DTPA), to which PEG-chains of exact molecular weight (1-(*tert*-butoxycarbonyl-amino)-4,7,10-trioxa-13-tridecanamine) were incorporated. The DTPA derivative contains an alkyne moiety at its focal point instead of a carboxylic one, and was synthesized as follows (Scheme 2). Initially, *tert*-butyl bromoacetate was reacted with ethanolamine, after which HO/Br exchange using N-bromosuccinimide (NBS) and PPh₃ afforded compound **7** in good yield (71 %), as confirmed by HPLC-MS and NMR (Figures S9-S10 in supporting information). The main NMR data for this compound in the ¹H NMR spectrum are the singlet at δ 3.48 for the CH₂CO group and the triplets at δ 3.13 and 3.48 for the -N(CH₂)₂Br chain. The alkyne DTPA derivative **8** was then obtained by coupling two units of **7** to propargylamine (83 % yield). This resulted to be the key step in the synthesis of the final dendron because we were able to minimize the overalkylation of the propargylamine. The best results were achieved using DIEA as base (2 equiv.) and heating at 80 °C. The presence of the propargylamino fragment gave rise to a shifting to lower frequency of the N(CH₂)₂N chain to δ 2.66 and 2.84 in the ¹H NMR spectrum (Figures S11-S12 in supporting information).

Afterwards, the *tert*-butyl groups were removed under acidic conditions and the PEG-chains were introduced by amide bond formation, rendering the desired dendron **10** in satisfactory yield (84 %), which was characterized by NMR (Figures S13-S14 in supporting information), HPLC-MS and HR-MS. In this compound, the presence of the new amide groups were distinguished in ¹H NMR spectroscopy by means of one broad resonance at δ 7.51 for the NH protons, whereas the NH protons of the NHBoc groups were observed as a broad resonance at δ 5.10.



Scheme 2. Synthesis of **10**. i) KHCO_3 , DMF, r. t., 22 h; ii) NBS, PPh_3 , CH_2Cl_2 , 0°C , 2 h; iii) $\text{NH}_2\text{C}_3\text{H}_3$, DIPEA, CH_3CN , 24 h, 80°C ; iv) HCl /dioxane, 16 h, r. t.; v) Boc-1-amino-4,7,10-trioxa-13-tridecanamine, CH_2Cl_2 :DMF (7:3, v:v), solid PyBOP, DIPEA (pH = 8), 1 h, r. t.

The coupling of azide carbosilane dendrons $\text{N}_3\text{G}_n(\text{NHBoc})_m$ (**4-6**) with alkyne PEG-based wedge **10** was carried out in THF/ H_2O in the presence of Cu^+ at 60°C (Scheme 3), leading to the hybrid dendrimers **11-13**. The yield of this reaction was dependent on the generation of carbosilane dendron. While compounds **11** and **12** were obtained in acceptable yield (*ca.* 80 %), compound **13** was isolated in very low yield (23 %). The formation of amphiphilic dendrimers was confirmed by NMR spectroscopy (Figures S15-S18 in supporting information). The ^1H NMR spectra showed one resonance at about δ 7.50 for the CH proton of the triazole ring and the ^{13}C NMR spectra showed resonances at about δ 122 and δ 144 for the CH and *i*-C carbons of this ring, respectively. With respect to the two CH_2 groups bound to the triazole ring, the one stemming from the carbosilane dendron was observed about δ 4.30 in ^1H NMR spectroscopy and at about δ 50.0 in ^{13}C NMR spectroscopy, whereas the one derived from the PEG-based dendron was observed at around δ 3.70 in ^1H NMR spectroscopy and at about δ 46.0 in ^{13}C NMR spectroscopy.



Scheme 3. Synthesis of amphiphilic cationic dendrimers from carbosilane dendrons $\text{N}_3\text{G}_n(\text{NHBoc})_m$ (**4-6**) and PEG-based dendron **10**. i) CuSO_4 , NaAsc, NEt_3 , THF/ H_2O (6:2 v:v), 16 h, 60°C ; ii) HCl/dioxane, 5 h, r. t.

Treatment of NHBoc dendrimers **11-13** with excess HCl in dioxane led to the corresponding amphiphilic cationic dendrimers **14-16** (Scheme 3, Figure 1), which were isolated as white powders that were soluble in H_2O , in contrast to the starting compounds. The main NMR data (Figures S19-S22 in supporting information) of these compounds are, on the one hand, the disappearance of the *t*Bu resonances of Boc groups and, on the other hand, the resonances for the NH_3^+ protons observed in the ^1H NMR spectra about δ 8.00 (DMSO- d_6). In addition, in Figure 1, the analog carbosilane homodendrimer of generation 2, named as **17**,³⁵ is also depicted for structural comparison.




Figure 1. Drawing of cationic amphiphilic dendrimers **14-16** described in this study and generation two carbosilane dendrimer **17** used as a reference model in biomedical assays.

3. Biomedical assays

The potential application of amphiphilic dendrimers **14** and **15** for gene therapy, with 6 and 8 ammonium NH_3^+ groups respectively, was studied against HIV in PBMC and compared with that of the carbosilane homodendrimer **17**³⁵ with 8 NH_3^+ groups (Figure 1). The very low yield obtained in the synthesis of the amphiphilic dendrimer **16** precluded its use in these studies.

First, we tested the toxicity of these dendrimers by MTT assays to measure mitochondrial metabolic activity (Figure 2A). Compounds **14** and **15** were non-toxic up to 5 and 10 μM respectively, whereas carbosilane dendrimer **17** showed toxicity over 1 μM . Although it is clear that the presence of PEG fragments diminished the toxicity, the carbosilane moiety also might play a role, as the toxicity of **14** was slightly higher than that of **15**, with more cationic groups at the surface.




Figure 2. Cytotoxicity (MTT) of dendrimers **14**, **15** and **17** (A) and the corresponding dendriplexes (B) at variable siRNA Nef:dendrimer charge ratios (-/+) in PBMC with siRNA Nef concentration of 25 nM. Dextrane (5 μM) and DMSO (15%) were used as positive and negative controls respectively.

Also, the toxicity of dendriplexes was evaluated by MTT (Figure 2B). These experiments showed again higher tolerance for dendriplexes formed by Janus-type dendrimers **14** and **15** than for carbosilane homodendrimer **17**. Dendriplexes formed by dendrimer **14** were biocompatible up to a siRNA:dendrimer ratio of 1:4 (-/+), dendriplexes containing **15** up to a ratio of 1:8 (-/+) and finally dendriplexes with **17**

were non-toxic only below a ratio of 1:2 (-/+). These results are in agreement with the toxicity observed for dendrimers alone.

Electrophoresis analyses in agarose gel were performed to study the binding capacity of these dendrimers toward siRNA Nef (Figure 3). Amphiphilic dendrimer **14** formed a complex with siRNA Nef from a ratio of 1:4 (-/+) at 2 h but released it after 24 h, being stable over time at a higher ratio. However, dendritic systems with 8 NH_3^+ groups, **15** and **17**, formed more stable complexes in which the cargo was not released after 24 h. For amphiphilic dendrimer **15**, the dendriplex was formed from ratios 1:8 (-/+) but for carbosilane homodendrimer **17** stable dendriplexes were generated from ratios 1:1 (-/+). In any case, the presence of PEG units in these Janus-type dendrimers clearly weakened the interaction with siRNA.




Figure 3. Electrophoresis gel in agarose of dendriplexes at different siRNA Nef:dendrimer charge ratios after 2 h (3A) and 24 h (3B).




Figure 4. Polyacrylamide gel electrophoresis of dendriplexes/heparin competition assays after 24 h. The y-axis denotes free siRNA while concentration of heparin was measured in International Units of heparine per μg of siRNA ($\text{U}/\mu\text{g}$).

In order to test the strength of the interaction between siRNA and dendrimers, heparin competition assays were performed (Figure 4). The $-/+$ charge ratio of dendriplexes that has been used for this experiment corresponds with the best results found in the biocompatibility assays, 1:4 for compound **14**, 1:8 dendriplex for compound **15** and 1:2 dendriplex for compound **17**. Polyacrylamide gel electrophoresis (PAGE) was used to adequately visualize and quantify the siRNA released from the dendriplex as heparin concentration increased. It was found that such release process began at 0.1 $\text{U}/\mu\text{g}$ for the three types of dendriplexes. However, the influence of PEG units was clear again, as higher retention was shown by free-PEG dendrimer **17**. Analogous dendritic systems to the homodendrimers **17** containing $-\text{CH}_2\text{NMe}_3^+$ at the periphery resulted to be inactive regarding HIV inhibition when dendriplexes were used.⁴⁶ This drawback was ascribed to the high stability shown by the dendriplexes, which enabled them to internalize their cargo but prevented their release inside the cell for *in vitro* experiments. The presence of PEG moieties weakened these interactions, which could be a key feature in transfection processes.

Because of the charge ratio is different for every dendrimer used, it seems difficult to compare among them in term of relative strength. However, it is also plausible that the difficulty on releasing the siRNA may increase on increasing the charge ratio at least until certain limits. Therefore, if a 1:4 charge ratio

(-/+) were used for dendrimers **15** instead of 1:8, higher liberation of siRNA may be observed while the opposite would be true if dendrimer **17** were tested at such ratio, supporting again the assumption of the influence of PEG units on the biological properties of the Janus dendrimers.

Zeta-potential and size measurement experiments have been carried out for dendriplexes formed by dendrimers **14**, **15** or **17** and siRNA-Nef (see Supporting Information). The differences between the charge ratio profiles of dendriplexes measured by Z-potential corroborate the intensity of interactions between different dendrimers and siRNA. The lower zeta-potential values observed for **14** and **15** respecting **17** dendriplexes with siRNA show more efficiency in term of transfection and biocompatibility. Although, a positive charge on surface dendriplex facilitates cell absorption and mediates efficient endosomal uptake, high positive charges imply cytotoxicity and non-specific binding to others biological components. However, respecting particle size, no rational data were obtained for comparing among different dendriplexes.

Finally, a post-treatment inhibitory study on PBMC by p24 ELISA assay was done to determine the capacity of dendrimer/siRNA Nef dendriplexes to interfere in HIV replication (Figure 5). The efficiency of siRNA delivery is close related to the formation of p24 antigen. The siNef inhibit the formation of the viral Nef protein which is vital for the formation of new viral particles represented by the detection of the p24 antigen. The p24 protein is present in the HIV core; therefore quantification of this antigen is a method to evaluate the inhibition ability of any system once the cells are infected. Of the three systems used, the one formed with Janus-type dendrimer **15** gave the best results, showing inhibition of up to 50 %. This result marks a clear difference with respect to those obtained for the dendriplexes formed with Janus-type dendrimer **14** and homodendrimer **17**. Thus, siRNA delivery is more favorable in the case of dendriplex formed with **15**, an observation that corroborates the electrophoregrams described previously, although release of siRNA from **15** is less than from **14** (see Fig. 3 and 4), whereas the retention strength of dendrimer **17** with respect to the siRNA probably is the major drawback of this system. It is likely that the complex of siRNA with compound **15** has a unique structure, and/or larger excess dendritic

compounds might affect the efficient siRNA delivery. Finally, dendriplex of **15** showed an activity similar to that of the dendriplex formed with the well-known PEI system (at \pm charge ratio 1:2), XXX




Figure 5. HIV protein p24 ELISA test of infected PBMC after 48 h of treatment. AZT denotes zidovudine (replication inhibitor); T20 is enfuvirtide (fusion inhibitor); **14**, **15** and **17** mean inhibition in the presence of dendrimers alone below their cytotoxicity levels, 5, 10 and 1 μ M respectively; 14 1/4, 15 1/8 and 17 1/2 mean dendriplexes of the corresponding dendrimers at those \pm charge ratio. Dendriplexes with random siRNA were formed at the same charge ratio than siRNA Nef. siRNA concentrations of 250 nM were used. Incubation time for dendriplex formation was 15 minutes and incubation time of PBMC with HIV virus was 1 h.

4. Conclusions

The click coupling of azide carbosilane dendrons (generations 1 and 2) and alkyne PEG-based dendron has been successfully used as building blocks to synthesize Janus-type cationic dendrimers functionalized with 6 and 8 ammonium NH_3^+ groups. However, for higher generations this reaction was not successful, as very low yield was obtained when the corresponding carbosilane dendron of generation 3 was used. The performance of heterodendrimers **14** and **15** was compared with a carbosilane homodendrimer with 8 NH_3^+ groups (**17**) as gene delivery vectors against HIV in PBMC. The presence of the PEG moiety

afforded lower toxicities than the homodendrimer analog, and the same trend was observed when the corresponding dendriplexes were used. With respect to dendriplex strength, electrophoresis analyses showed that dendrimers **14** and **15** formed dendriplexes at higher ratios than the homodendrimer **17**, thus evidencing a weaker interaction between dendrimers and siRNA. This finding was corroborated by the dendriplex/heparin competition assays. Both lower toxicity and lower dendriplex strength, ascribed to the presence of PEG moieties, could be crucial properties for their use as carriers of nucleic material, as Janus-type dendrimer **15** showed greater HIV inhibitory activity than homodendrimer **17** containing the same number of positive charges.

4. Experimental Section

4.1. General Considerations. All reactions were carried out under inert atmosphere and solvents were purified from appropriate drying agents when necessary (THF). NMR spectra were recorded on a Varian Unity VXR-300 (300.13 (^1H), 75.47 (^{13}C) MHz) or on a Bruker AV400 (400.13 (^1H), 100.60 (^{13}C), 79.49 (^{29}Si) MHz). Chemical shifts (δ) are given in ppm. ^1H and ^{13}C resonances were measured relative to solvent peaks, considering TMS = 0 ppm. ^{29}Si resonances were measured relative to external TMS. When necessary, assignment of resonances was done from HSQC, HMBC, COSY, TOCSY and NOESY NMR experiments. Elemental analyses were performed on a Perkin-Elmer 240C. Mass spectra were obtained from an Agilent 6210 (ESI), a Bruker Ultraflex III (MALDI-TOF) and a Thermo Scientific LTQ-FT Ultra (HRMS). Analytical HPLC was carried out on a Waters (Ireland) instrument comprising a SunfireTM C18 reversed-phase analytical column, 3.5 μm , 4.6 x 100 mm, a separation module (Waters 2695), automatic injector, and photodiode array detector (Waters 2298). HPLC-MS analyses of peptide samples were carried out on a Waters (Ireland) instrument comprising a SunfireTM C18 reversed-phase analytical column, 3.5 μm , 4.6 x 100 mm, a separation module (Waters 2695), automatic injector, photodiode array detector (Waters 2298), and a Waters micromass ZQ unit. The zeta potential measurements were carried out with a Malvern NanoZS instrument. Compounds Karstedt's Pt catalyst, $\text{C}_3\text{H}_5\text{NHBoc}$, NaN_3 , NaAscorbate, tert-butyl bromoacetate, PPh_3 , NBS, propargylamine (Aldrich), 1-(tert-butyloxycarbonyl-

amino)-4,7,10-trioxa-13-tridecanamine (Iris Biotech) and CuSO₄ (Panreac) were obtained from commercial sources. Compounds BrG_n(SiH)_m (n = 1, m = 2; n = 2, m = 4; n = 3, m = 8)⁴⁵ and cationic carbosilane dendrimer **17**³⁵ were synthesized as published.

4.2. Synthesis of compounds.

NMR data of dendrimers and dendrons of first generation and compounds **7-10** are labeled with letters. The corresponding labeled NMR spectra and structures are collected in supporting information.

Synthesis of BrG1Boc2 (1). A solution of BrG₁(SiH)₂ (2.00 g, 5.24 mmol) and C₅H₃NHBoc (1.71 g, 10.90 mmol) in THF (5 mL) was stirred at 40 °C for 8 h in a teflon-valved ampoule in the presence of platinum Karstedt's catalyst. Afterwards the solvent was removed under vacuum, and **1** was purified by column chromatography (hexane:THF 5:2), which gave **1** as a colorless oil (2.88 g, 79 %). NMR data (CDCl₃): ¹H NMR: -0.09 (s, 3 H, SiMe (e)), -0.07 (s, 12 H, SiMe₂ (i)), 0.43 (m, 6 H, CH₂Si (j)), 0.52 (m, 8 H, CH₂Si (f, h)), 1.23 (m, 6 H, CH₂CH₂CH₂ (c, g)), 1.42 (s, 22 H, SiCH₂CH₂CH₂N and *t*Bu (k, n)), 1.78 (m, 2 H, BrCH₂CH₂CH₂CH₂ (b)), 3.06 (m, 4 H, CH₂NH (l)), 3.40 (t, J = 6.80 Hz, 2 H, BrCH₂ (a)), 4.54 (s, 2 H, NH (m)). ¹³C NMR: -5.1 (SiMe), -3.4 (SiMe₂), 12.4 (SiCH₂CH₂CH₂N), 13.0 (SiCH₂), 18.4, 18.6, 20.0 (SiCH₂ and SiCH₂CH₂), 22.4 (BrCH₂CH₂CH₂CH₂), 22.6 (BrCH₂CH₂CH₂CH₂), 24.6 (SiCH₂CH₂CH₂NH), 28.4 (CMe₃), 33.7 (BrCH₂CH₂CH₂CH₂), 36.3 (BrCH₂CH₂CH₂CH₂), 43.8 (CH₂N), 79.9 (CMe₃), 155.9 (NHCOO). ²⁹Si NMR: 1.8 (SiMe), 2.0 (SiMe₂). MS (MALDITOF): 695.3656 [M + H⁺]. Anal. Calc. for C₃₁H₆₇BrN₂O₄Si₃ (696.04): C, 53.46; H, 7.90; N, 4.02; Obt.: C, 53.32; H, 7.79; N, 3.94.

Synthesis of BrG2Boc4 (2). Following the procedure described above for **1**, from BrG₂(SiH)₄ (1.50 g, 1.99 mmol) and C₅H₃NHBoc (1.31 g, 8.35 mmol) in THF (3 mL) afforded **2** as a colorless oil (1.68 g, 61 %). NMR data (CDCl₃): ¹H NMR: -0.12 (s, 6 H, SiMe), -0.09 (s, 3 H, SiMe), -0.07 (s, 24 H, SiMe₂), 0.42 (m, 10 H, CH₂Si), 0.52 (m, 24 H, CH₂Si), 1.23 (m, 14 H, CH₂CH₂CH₂), 1.42 (s, 44 H, SiCH₂CH₂CH₂N and *t*Bu), 1.78 (m, 2 H, BrCH₂CH₂CH₂CH₂), 3.05 (m, 8 H, CH₂NH), 3.39 (t, J = 6.80 Hz, 2 H, BrCH₂), 4.57 (s, 4 H, NH). ¹³C NMR: -5.1 (SiMe), -5.0 (SiMe), -3.4 (SiMe₂), 12.4 (SiCH₂CH₂CH₂N), 13.0

(SiCH₂), 18.4, 18.8, 18.9, 20.0 (SiCH₂ and SiCH₂CH₂), 22.5 (BrCH₂CH₂CH₂CH₂ and BrCH₂CH₂CH₂CH₂), 24.6 (SiCH₂CH₂CH₂NH), 28.4 (CMe₃), 33.6 (BrCH₂CH₂CH₂CH₂), 36.4 (BrCH₂CH₂CH₂CH₂), 43.8 (CH₂N), 79.0 (CMe₃), 155.9 (NHCOO). ²⁹Si NMR: 1.7 (SiMe), 2.1 (SiMe₂). MS (MALDITOF): 1381.8389 [M + H⁺]. Anal. Calc. for C₆₅H₁₄₁BrN₄O₈Si₇ (1383.34): C, 56.44; H, 10.27; N, 4.05; Obt.: C, 56.26; H, 10.49; N, 4.27.

Synthesis of BrG3Boc8 (3). Following the procedure described above for **1**, from BrG₃(SiH)₈ (1.10 g, 0.73 mmol) and C₅H₃NHBoc (0.97 g, 6.16 mmol) afforded **3** as a colorless oil (1.27 g, 63 %) after size exclusion chromatography with THF. NMR data (CDCl₃): ¹H NMR: -0.11 (s, 21 H, SiMe), -0.07 (s, 48 H, SiMe₂), 0.43 (m, 18 H, CH₂Si), 0.52 (m, 56 H, CH₂Si), 1.23 (m, 30 H, CH₂CH₂CH₂), 1.42 (s, 88 H, SiCH₂CH₂CH₂N and *t*Bu), 1.78 (m, 2 H, BrCH₂CH₂CH₂CH₂), 3.04 (m, 16 H, CH₂NH), 3.39 (t, J = 6.80 Hz, 2 H, BrCH₂), 4.58 (s, 4 H, NH). ¹³C NMR: -4.9 (SiMe), -3.4 (SiMe₂), 12.4 (SiCH₂CH₂CH₂N), 13.6 (SiCH₂), 18.4, 18.5, 18.8, 19.0, 20.0 (SiCH₂ and SiCH₂CH₂), 22.5 (BrCH₂CH₂CH₂CH₂ and BrCH₂CH₂CH₂CH₂), 24.6 (SiCH₂CH₂CH₂NH), 28.4 (CMe₃), 33.6 (BrCH₂CH₂CH₂CH₂), 36.4 (BrCH₂CH₂CH₂CH₂), 43.8 (CH₂N), 78.9 (CMe₃), 156.0 (NHCOO). ²⁹Si NMR: 1.7 (SiMe), 2.1 (SiMe₂). Anal. Calc. for C₁₃₃H₂₈₉BrN₈O₁₆Si₁₅ (2757.95): C, 57.92; H, 10.96; N, 4.06; Obt.: C, 57.81; H, 10.49; N, 3.88.

Synthesis of N3G1Boc2 (4). A solution of **1** (1.50 g, 2.16 mmol) and NaN₃ (0.56 g, 8.62 mmol) in DMF (20 mL) was stirred at 80 °C for 16 h in a teflon-valved ampoule. Afterwards the solvent was removed under vacuum and extraction with Et₂O and brine was carried out. The organic phase was dried with MgSO₄ and filtered, and the solvent was removed under vacuum to give **4** as a colorless oil (1.28 g, 87 %). NMR data (CDCl₃): ¹H NMR: -0.09 (s, 3 H, SiMe (e)), -0.07 (s, 12 H, SiMe₂ (i)), 0.43 (m, 6 H, CH₂Si (d, j)), 0.51 (m, 8 H, CH₂Si (f, h)), 1.27 (m, 6 H, CH₂CH₂CH₂ (c, g)), 1.42 (s, 22 H, SiCH₂CH₂CH₂N (k) and *t*Bu (p)), 1.60 (m, 2 H, N₃CH₂CH₂ (b)), 3.05 (m, 4 H, CH₂NH (l)), 3.25 (t, J = 6.8 Hz, 2 H, N₃CH₂ (a)), 4.54 (s, 2 H, NH (m)). ¹³C NMR: -5.1 (SiMe), -3.4 (SiMe₂), 12.4 (SiCH₂CH₂CH₂N), 13.6 (SiCH₂), 18.4, 18.6, 20.0 (SiCH₂ and SiCH₂CH₂), 21.2 (N₃CH₂CH₂CH₂CH₂), 24.6 (SiCH₂CH₂CH₂NH), 28.4 (CMe₃), 32.7 (N₃CH₂CH₂), 43.8 (CH₂N), 51.1 (N₃CH₂), 79.0 (CMe₃),

155.9 (NHCOO). ^{29}Si NMR: 1.7 (SiMe), 2.0 (SiMe₂). MS (MALDITOF): 658.4531 [M + H]⁺. Anal. Calc. for C₃₁H₆₇N₅O₄Si₃ (658.15): C, 56.57; H, 10.26; N, 10.64; Obt.: C, 56.42; H, 10.13; N, 10.21.

Synthesis of N3G2Boc4 (5). Following the procedure described above for **4**, from **2** (1.22 g, 0.88 mmol) and NaN₃ (0.23 g, 3.53 mmol) afforded **5** as a colorless oil (1.03 g, 87 %). NMR data (CDCl₃): ^1H NMR: -0.09 (s, 3 H, SiMe), -0.09 (s, 6 H, SiMe), -0.07 (s, 24 H, SiMe₂), 0.43 (m, 10 H, CH₂Si), 0.51 (m, 24 H, CH₂Si), 1.27 (m, 14 H, CH₂CH₂CH₂), 1.42 (s, 44 H, SiCH₂CH₂CH₂N and *t*Bu), 1.60 (m, 2 H, N₃CH₂CH₂), 3.05 (m, 8 H, CH₂NH), 3.25 (t, J = 6.8 Hz, 2 H, N₃CH₂), 4.54 (s, 4 H, NH). ^{13}C NMR: -5.1 (SiMe), -5.0 (SiMe), -3.4 (SiMe₂), 12.4 (SiCH₂CH₂CH₂N), 13.5 (SiCH₂), 18.4, 18.5, 18.8, 18.9, 20.0 (SiCH₂ and SiCH₂CH₂), 21.2 (N₃CH₂CH₂CH₂CH₂), 24.6 (SiCH₂CH₂CH₂NH), 28.4 (CMe₃), 32.6 (N₃CH₂CH₂), 43.8 (CH₂N), 51.1 (N₃CH₂), 78.9 (CMe₃), 155.9 (NHCOO). ^{29}Si NMR: 1.7 (SiMe), 2.0 (SiMe₂). MS (MALDITOF): 1344.9293 [M + H]⁺. Anal. Calc. for C₆₅H₁₄₁N₇O₈Si₇ (1345.46): C, 58.02; H, 10.56; N, 7.29; Obt.: C, 58.21; H, 10.33; N, 7.11.

Synthesis of N3G3Boc8 (6). Following the procedure described above for **4**, from **3** (1.05 g, 0.38 mmol) and NaN₃ (0.062 g, 0.95 mmol) afforded **6** as a white wax (0.82 g, 80 %). NMR data (CDCl₃): ^1H NMR: -0.11 (s, 21 H, SiMe), -0.07 (s, 48 H, SiMe), 0.43 (m, 18 H, CH₂Si), 0.51 (m, 56 H, CH₂Si), 1.27 (m, 30 H, CH₂CH₂CH₂), 1.42 (s, 88 H, SiCH₂CH₂CH₂N and *t*Bu), 1.60 (m, 2 H, N₃CH₂CH₂), 3.05 (m, 16 H, CH₂NH), 3.25 (t, J = 6.8 Hz, 2 H, N₃CH₂), 4.59 (bs, 8 H, NH). ^{13}C NMR: -5.1 and -5.0 (SiMe), -3.4 (SiMe₂), 12.4 (SiCH₂CH₂CH₂N), 13.5 (SiCH₂), 18.4, 18.5, 18.8, 18.9, 20.0 (SiCH₂) and SiCH₂CH₂), 21.2 (N₃CH₂CH₂CH₂CH₂), 24.6 (SiCH₂CH₂CH₂NH), 28.4 (CMe₃), 32.6 (N₃CH₂CH₂), 43.8 (CH₂N), 51.1 (N₃CH₂), 78.9 (CMe₃), 156.0 (NHCOO). ^{29}Si NMR: 1.7 (SiMe), 2.1 (SiMe₂). Anal. Calc. for C₁₃₃H₂₈₉N₁₁O₁₆Si₁₅ (2720.06): C, 58.73; H, 10.71; N, 5.66; Obt.: C, 58.99; H, 10.87; N, 5.31.

Synthesis of 2-[Bis-(*tert*-butyloxycarbonylmethyl)amino]ethyl bromide (7).

KHCO₃ was added (6.18 g, 61.8 mmol, 2.5 eq.) to a solution of *tert*-butyl bromoacetate (8.05 mL, 54.5 mmol, 2.2 eq.) in 50 mL of anhydrous DMF. The suspension was cooled at 0 °C, ethanolamine (1.48 mL, 24.5 mmol, 1 eq.) was added via a syringe over a 5-min period, and the solution was stirred at 0 °C for 30 min. The reaction mixture was then allowed to warm to room temperature and stirred for 22 h. After this

time, most of the DMF was evaporated under vacuum and 50 mL of saturated NaHCO₃ was added. The resulting mixture was extracted with diethyl ether (3×50 mL), and the combined organic phases were washed with 50 mL of brine, dried with Na₂SO₄, and evaporated to afford the crude product *N,N*-bis[(*tert*-butoxycarbonyl)methyl]-2-hydroxyethylamine (7.41 g) as an oil. This crude product was dissolved in CH₂Cl₂ and solid PPh₃ (8.66 g, 33.0 mmol, 1.3 eq.) was added to the solution that was cooled at 0 °C. After that, solid NBS (5.87 g, 33.0 mmol, 1.3 eq.) was added over a 5-min period and the mixture was stirred for 2 h at 0 °C. After this time the solvent was evaporated and a semisolid residue was obtained, which was then triturated with diethyl ether. The solid was filtered, washed with ether and discarded, and the ether phase was evaporated to afford an oily residue, which was purified by flash chromatography on silica (5→30% diethyl ether in hexane) yielding **7** (6.18 g, 71%).

NMR data of *N,N*-bis[(*tert*-butoxycarbonyl)methyl]-2-hydroxyethylamine (CDCl₃): ¹H NMR: 1.45 (s, 18 H, *t*Bu), 2.82 (t, J = 4.89 Hz, 2 H, HOCH₂CH₂), 3.38 (s, 2 H, NCH₂CO), 3.46 (t, J = 4.98 Hz, 4 H, HOCH₂CH₂), and 3.64 (bs, OH); ¹³C NMR: 27.9 (CMe₃), 56.5 (NCH₂CO), 56.9 (HOCH₂CH₂), 58.2 (HOCH₂CH₂), 81.3 (CMe₃), 171.2 (NCH₂CO). MS: Theoretical mass for C₁₄H₂₇O₅N: 289.2; Mass found by HPLC-MS: 290.1 (M+1).

NMR data of **7** (CDCl₃): ¹H NMR: 1.46 (s, 18 H, *t*Bu (d)), 3.13 (t, J = 7.82 Hz, 2 H, BrCH₂CH₂ (b)), 3.44 (t, J = 7.82 Hz, 2 H, BrCH₂CH₂ (a)), and 3.48 (s, 4 H, NCH₂CO (c)). ¹³C NMR: 28.1 (CMe₃), 30.2 (BrCH₂CH₂), 56.5 (NCH₂CO), 56.6 (BrCH₂CH₂), 81.2 (CMe₃), 170.5 (NCH₂CO).. MS: Theoretical mass for C₁₄H₂₆BrO₄N: 351.1; Mass found by HPLC-MS: 352.0 (M+1).

Synthesis of 4-(Prop-2-ynyl)-1,1,7,7-tetra(*tert*-butoxycarbonylmethyl)-1,4,7-triazaheptane (8**).**

Propargylamine (0.103 mL, 1.61 mmol) and DIEA (1.285 mL, 7.0 mmol) were added to a solution of bromoderivative **7** (1.250 g, 3.55 mmol) in 100 mL of acetonitrile,. The resulting mixture was stirred at 80 °C for 24 h. Afterwards the acetonitrile was evaporated, and the resulting oil was dissolved in ethyl acetate. The organic phase was washed three times with an aqueous solution of 5% NaHCO₃, dried over MgSO₄ and evaporated. The yellow oil obtained was flash chromatographed on basic aluminum oxide (5→20% ethyl acetate in hexane), affording compound **8** (0.80 g, 83%). NMR data (CDCl₃): ¹H NMR:

1.45 (s, 36 H, *t*Bu (f)), 2.15 (t, *J* = 2.2 Hz, 1 H, NCH₂CCH (a)), 2.66 (t, *J* = 6.9 Hz, 4 H, NCH₂CH₂NCH₂CH₂N (c)), 2.84 (t, 6.9 Hz, 4 H, NCH₂CH₂NCH₂CH₂N (d)), 3.46 (s, 8 H, NCH₂CO (e)), 3.54 (d, *J* = 2.2 Hz, 2 H, NCH₂CCH (b)); ¹³C NMR: δ: 28.2 (CMe₃), 42.0 (NCH₂CCH), 51.7 (NCH₂CH₂NCH₂CH₂N), 52.1 (NCH₂CH₂NCH₂CH₂N), 56.1 (NCH₂CO), 73.0 (NCH₂CCH), 78.7 (NCH₂CCH), 80.8 (CMe₃), 170.7 (NCH₂CO). MS: Theoretical mass for C₃₁H₅₅N₃O₈: 597.4. Experimental mass detected by LC-MS: 598.0 (M+1). Experimental mass detected by HRMS: 598.4060 (M+1).

Synthesis of 4-(prop-2-ynyl)-1,1,7,7-tetra(carboxymethyl)-1,4,7-triazaheptane (9).

Compound **8** (0.400 g, 0.66 mmol) was dissolved in 4.0 M HCl in dioxane (10 mL, 40 mmol) and the mixture was stirred overnight at room temperature. HCl and dioxane were then removed by evaporation and the resulting crude product was coevaporated with dioxane (× 3), affording compound **9** as the corresponding hydrochloride salt (0.360 g), which was used for the next step without further purification.

Synthesis of alkyne-functionalized PEG dendron 10.

Solid PyBOP (1.510 g, 2.90 mmol) and 1-(*tert*-butyloxycarbonyl-amino)-4,7,10-trioxa-13-tridecanamine (0.930 g, 2.90 mmol,) dissolved in 10 mL of CH₂Cl₂ were added to a solution of compound **9** in 500 mL of anhydrous CH₂Cl₂:DMF (7:3, v:v). The pH was adjusted to 8 with DIEA. After 1 h of stirring at room temperature, the solvents were removed in vacuo. The resulting crude product was dissolved in 100 mL of CH₂Cl₂ and washed with 5% NaHCO₃ (3× 100 mL). The organic phase was evaporated, and the resulting crude product dissolved in CH₂Cl₂ (10 mL), was transferred to a 50-mL tube, and then hexane (40 mL) was added. The mixture was stirred vigorously and centrifuged. The supernatant was discarded, and the remaining oily precipitate corresponded to pure compound **10** (0.877 g, 84 % yield). NMR data (CDCl₃): ¹H NMR: δ 1.43 (s, 36 H, *t*Bu (r)), 1.78 (m, 16 H, NHCH₂CH₂CH₂O (h)), 2.26 (t, *J* = 2.2 Hz, 1 H, NCH₂CCH (a)), 2.64 (m, 8 H, NCH₂CH₂NCH₂CH₂N (c, d)) 3.21 (m, 16 H, NCH₂CH₂CH₂O (g,p)), 3.34 (m, 8 H, NCH₂CO (e)), 3.39 (d, *J* = 1.6 Hz, 2H, NCH₂CCH (b)), 3.53 (m, 16 H, NHCH₂CH₂CH₂O (n, i)), 3.57-3.66 (m, 32 H, OCH₂CH₂O (j-m)), 5.10 (bs, NH (q)), 7.51 (bs, NH (f)). ¹³C NMR (CDCl₃): δ 28.4 (CMe₃), 29.5 (OCONHCH₂CH₂CH₂O), 29.7 (NCH₂CONCH₂CH₂CH₂O), 37.1 (NCH₂CONCH₂CH₂CH₂O), 38.4 (OCONHCH₂CH₂CH₂O), 46.2 (NCH₂CCH), 51.7

(NCH₂CH₂NCH₂CH₂N), 53.2 (NCH₂CH₂NCH₂CH₂N), 59.0 (NCH₂CO), 69.4 (OCONHCH₂CH₂CH₂O), 69.5 (NCH₂CONHCH₂CH₂CH₂O), 70.2 (OCH₂CH₂O), 73.9 (CMe₃), 77.8 (NCH₂CCH), 78.9 (NCH₂CCH), 156.0 (OCONHCH₂CH₂CH₂O), 170.7 (NCH₂CONCH₂CH₂CH₂O). MS: Theoretical mass for C₇₅H₁₄₃N₁₁O₂₄: 1582.03. Experimental mass detected by LC-MS: 792.64 ((M+2)/2). Experimental mass detected by HRMS: 1583.0358 (M+1).

Synthesis of dendrimer 11. Compounds **4** (0.069 g, 0.104 mmol) and **10** (0.150 g, 0.095 mmol) were stirred under argon atmosphere in a mixture of THF/H₂O (6/2 ml) at 40°C in the presence of CuSO₄ (7% mol), NaAscorbate (15% mol) and NEt₃ (20% mol) for 16 h. Afterwards, the reaction was treated with few drops of NH₄OH (30%) and the product was extracted with AcOEt against a saturated water solution of NH₄Cl. The organic phase was dried with MgSO₄, the solvent was removed under vacuum, and the remaining oil was washed with hexane (10 mL) to give compound **11** as yellowish oil (0.176 g, 83 %). NMR data (CDCl₃): ¹H NMR: -0.07 (s, 15 H, SiMe (e, i)), 0.47 (m, 6 H, CH₂Si (d,j)), 0.52 (m, 8 H, CH₂Si (f, h)), 1.23 (m, 6 H, CH₂CH₂CH₂ (c, g)), 1.41 (m, 58 H, SiCH₂CH₂CH₂N and *t*Bu (k, n, r')), 1.73 (m, 16 H, OCH₂CH₂CH₂N (o')), 1.89 (m, 2 H, N-NCH₂CH₂ (b)), 2.54 (t, J = 7.3 Hz, 2 H, NCH₂CH₂N (c')), 2.68 (t, J = 7.3 Hz, 2 H, NCH₂CH₂N (d')), 3.04 (m, 4 H, CH₂NH (l)), 3.16 (m, 16 H, CH₂NH and CH₂CO), 3.28 (m, 8 H, CH₂NH), 3.45-3.60 (m, 48 H, OCH₂ (j'-m')), 3.70 (s, 2 H, C_{sp}CH₂N (b')), 4.31 (t, J = 6.8 Hz, 2 H, CH₂NN (a)), 4.64 (br. s, 2 H, NH (m)), 5.05 (br. s, 4 H, NH (q')), 7.50 (s, 1 H, C_{sp}H (a')), 7.75 (br. s, 4 H, NH (f')). ¹³C NMR: -5.1 (SiMe), -3.3 (SiMe₂), 12.4 (SiCH₂CH₂CH₂N), 13.6 (SiCH₂), 18.4, 18.7, 20.0, 21.2 (SiCH₂ and SiCH₂CH₂), 24.7 (SiCH₂CH₂CH₂NH), 28.5 (CMe₃), 29.6 and 29.7 (NHCH₂CH₂CH₂O), 34.3 (N-NCH₂CH₂), 37.0 (CH₂NH), 38.5 (CH₂NH), 43.8 (CH₂NH), 46.3 (C_{sp}CH₂N), 50.1 (CH₂NN), 51.4 (NCH₂CH₂N), 52.7 (NCH₂CH₂N), 58.9 (CH₂CO), 69.4, 69.5, 70.2, 70.5 (OCH₂), 78.9 (CMe₃), 122.7 (CH=C), 143.5 (CH=C), 156.1 (NHCOO), 170.9 (NHCOCH₂). Anal. Calc. for C₁₀₆H₂₁₀N₁₆O₂₈Si₃ (2241.15): C, 56.81; H, 9.44; N, 10.00; Obt.: C, 56.59; H, 9.26; N, 9.74.

Synthesis of dendrimer 12. Following the procedure described for **11**, reaction of **5** (0.147 g, 0.109 mmol) and **10** (0.150 g, 0.095 mmol) at 40°C afforded **12** as yellowish oil (0.222 g, 80 %). NMR data (CDCl₃): ¹H NMR: -0.11 (s, 9 H, SiMe), -0.07 (s, 24 H, SiMe), 0.47 (m, 10 H, CH₂Si), 0.52 (m, 24 H,

CH_2Si), 1.23 (m, 14 H, $\text{CH}_2\text{CH}_2\text{CH}_2$), 1.41 (m, 80 H, $\text{SiCH}_2\text{CH}_2\text{CH}_2\text{N}$ and *t*Bu), 1.73 (m, 16 H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{N}$), 1.89 (m, 2 H, $\text{N-NCH}_2\text{CH}_2$), 2.54 (t, $J = 7.3$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{N}$), 2.68 (t, $J = 7.3$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{N}$), 3.04 (m, 8 H, CH_2NH), 3.16 (m, 16 H, CH_2NH , CH_2CO), 3.28 (m, 8 H, CH_2NH), 3.45-3.60 (m, 48 H, OCH_2), 3.70 (s, 2 H, $\text{C}_{\text{sp}}\text{CH}_2\text{N}$), 4.30 (t, $J = 6.8$ Hz, 2 H, CH_2NN), 4.64 (br. s, 4 H, NH), 5.05 (br. s, 4 H, NH), 7.48 (s, 1 H, $\text{C}_{\text{sp}}\text{H}$), 7.73 (br. s, 4 H, NH). ^{13}C NMR: -5.2 (SiMe), -4.9 (SiMe), -3.4 (SiMe₂), 12.4 (SiCH₂CH₂CH₂N), 15.3 (SiCH₂), 18.4, 18.7, 18.8, 19.0, 20.0, 21.2 (SiCH₂ and SiCH₂CH₂), 24.6 (SiCH₂CH₂CH₂NH), 28.5 (CMe₃), 29.7 (NHCH₂CH₂CH₂O), 34.3 (N-NCH₂CH₂), 37.0 (CH₂NH), 38.4 (CH₂NH), 43.8 (CH₂NH), 46.3 (C_{sp}CH₂N), 50.1 (CH₂NN), 51.4 (NCH₂CH₂N), 52.7 (NCH₂CH₂N), 58.7 (CH₂CO), 69.3, 69.5, 70.2, 70.4, 70.5 (OCH₂), 78.9 (CMe₃), 122.7 (CH=C), 143.5 (CH=C), 156.1 (NHCOO), 170.9 (NHCOCH₂). Anal. Calc. for C₁₄₀H₂₈₄N₁₈O₃₂Si₇ (2928.45): C, 57.42; H, 9.77; N, 8.61; Obt.: C, 57.31; H, 9.55; N, 8.44.

Synthesis of dendrimer 13. Following the procedure described for **11**, reaction of **6** (0.151 g, 0.056 mmol) and **10** (0.080 g, 0.051 mmol) at 60°C afforded **13** as yellowish oil (0.050 g, 23 %), after washing with hexane (5 ml) and purification through size-exclusion chromatography. NMR data (CDCl₃): ^1H NMR: -0.07 (s, 15 H, SiMe), 0.47 (m, 6 H, CH_2Si), 0.52 (m, 8 H, CH_2Si), 1.23 (m, 6 H, $\text{CH}_2\text{CH}_2\text{CH}_2$), 1.41 (m, 122 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{N}$ and *t*Bu), 1.73 (m, 16 H, $\text{OCH}_2\text{CH}_2\text{CH}_2\text{N}$), 1.89 (m, 2 H, N-NCH_2), 2.54 (t, $J = 7.3$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{N}$), 2.68 (t, $J = 7.3$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{N}$), 3.04 (m, 16 H, CH_2NH), 3.16 (m, 16 H, CH_2NH , CH_2CO), 3.28 (m, 8 H, CH_2NH), 3.45-3.60 (m, 48 H, OCH_2), 3.70 (s, 2 H, $\text{C}_{\text{sp}}\text{CH}_2\text{N}$), 4.30 (t, $J = 6.8$ Hz, 2 H, CH_2NN), 4.64 (br. s, 8 H, NH), 5.05 (br. s, 4 H, NH), 7.48 (s, 1 H, $\text{C}_{\text{sp}}\text{H}$), 7.73 (br. s, 4 H, NH). ^{13}C NMR: -5.1 (SiMe), -3.4 (SiMe₂), 12.3 (SiCH₂CH₂CH₂N), 18.3, 18.7, 18.8, 19.0, 19.7 (SiCH₂ and SiCH₂CH₂), 23.3 (SiCH₂CH₂CH₂NH), 28.3 (CMe₃), 29.5 (NHCH₂CH₂CH₂O), 34.3 (N-NCH₂CH₂), 36.8 (CH₂NH), 38.3 (CH₂NH), 43.6 (CH₂NH), 46.3 (C_{sp}CH₂N), 50.1 (CH₂NN), 51.4 (NCH₂CH₂N), 52.7 (NCH₂CH₂N), 58.7 (CH₂CO), 69.1-70.4 (OCH₂), 78.7 (CMe₃), 129.4 (CH=C), 142.4 (CH=C), 155.8 (NHCOO), 155.9 (NHCOO), 170.7 (NHCOCH₂). Anal. Calc. for C₂₀₈H₄₃₂N₂₂O₄₀Si₁₅ (4303.06): C, 58.06; H, 10.12; N, 7.16; Obt.: C, 57.81; H, 9.98; N, 7.02.

Synthesis of dendrimer 14. Compound **11** (0.150 g, 0.067 mmol) was mixed in CH₂Cl₂/H₂O (5 mL each) and then excess HCl was added (8.04 mmol), and the suspension was stirred at ambient temperature for 3 h. Afterwards, volatiles were removed under vacuum, and the solid was washed with Et₂O (2 x 15 ml) and finally ultrafiltrated with a membrane of MWCO = 500 to give compound **14** as white powder (0.113 g, 91%). NMR data (DMSO-d₆): ¹H NMR: -0.05 (s, 3 H, SiMe (e)), -0.02 (s, 12 H, SiMe₂ (i)), 0.55 (m, 14 H, CH₂Si (f, h, j)), 1.30 (m, 10 H, CH₂CH₂CH₂ and SiCH₂CH₂CH₂N (c, g, k)), 1.65-1.85 (m, 22 H, CH₂CH₂CH₂N (b, h', o')), 2.73 (m, 2 H, NCH₂CH₂N (c')), 2.80 (m, 2 H, NCH₂CH₂N (d')), 3.05 (m, 2 H, NCH₂CH₂N (d')), 3.15-3.40 (m, 20 H, CH₂NH and CH₂NH (l, n', p')), 3.50-3.90 (m, 58 H, CH₂CO and OCH₂ (b', j'-m')), 4.35 (m, 2 H, CH₂NN (a)), 7.67 (m, 1 H, C_{sp}H (a')), 8.14 (br. s, 30 H, NH₃⁺ (m, q')), 8.74 (br. s, 4 H, NH (f')). ¹³C NMR: -5.4 (SiMe), -3.9 (SiMe₂), 11.1 (SiCH₂CH₂CH₂N), 13.6 (SiCH₂), 17.5, 18.7, 21.1, 21.8, 22.5 (SiCH₂ and SiCH₂CH₂), 28.7, 29.2, (NCH₂CH₂CH₂O), 35.0 (N-NCH₂CH₂), 36.2 (CH₂NH), 41.1 (CH₂NH₃), 46.3 (C_{sp}CH₂N), 55.2 (NCH₂CH₂N), 59.3 (CH₂CO), 68.8-69.5 (OCH₂), 122.7 (CH=C), 143.5 (CH=C), 165.8 (NHCOCH₂). Anal. Calc. for C₇₆H₁₆₈Cl₆N₁₆O₁₆Si₃ (1859.22): C, 49.10; H, 9.11; N, 12.05; Obt.: C, 48.77; H, 8.90; N, 11.91.

Synthesis of dendrimer 15. Following procedure described for **14**, reaction of **12** (0.150 g, 0.051 mmol) and excess HCl in Et₂O (12.24 mmol) afforded **15** as white powder (0.111 g, 90%). NMR data (DMSO-d₆): ¹H NMR: -0.07 (s, 33 H, SiMe and SiMe₂), 0.55 (m, 30 H, CH₂Si), 1.30 (m, 14 H, CH₂CH₂CH₂ and SiCH₂CH₂CH₂N), 1.50-1.87 (m, 26 H, CH₂CH₂CH₂N), 2.70 and 2.80 (m, 8 H, CH₂NH₃⁺), 3.05 (m, 4 H, NCH₂CH₂N), 3.30-3.67 (br. s, 66 H, CH₂NH, C_{sp}CH₂N, CH₂CO and OCH₂), 4.24 (m, 2 H, CH₂NN), C_{sp}H not observed, 8.14 (br. s, 36 H, NH₃⁺), CONH not observed. ¹³C NMR: -5.4 (SiMe), -3.9 (SiMe₂), 11.1 (SiCH₂CH₂CH₂N), 13.6 (SiCH₂), 17.5-22.1 (SiCH₂ and SiCH₂CH₂), 28.7, 29.2, (NCH₂CH₂CH₂O), 35.4 (CH₂), 41.1 (CH₂NH₃), 59.3 (CH₂CO), 68.8-69.5 (OCH₂), not observed (CH=C, CH=C and 165.8 NHCOCH₂). Anal. Calc. for C₁₀₀H₂₂₈Cl₈N₁₈O₁₆Si₇ (2419.21): C, 49.65; H, 9.50; N, 10.42; Obt.: C, 49.33; H, 9.31; N, 10.24.

Synthesis of dendrimer 16. Following procedure described for **14**, reaction of **13** (0.075 g, 0.017 mmol) and excess HCl in Et₂O (8.16 mmol) afforded **16** as white powder (0.055 g, 89%). NMR data

(DMSO-d₆): ¹H NMR: -0.07 (s, 69 H, SiMe and SiMe₂), 0.55 (m, 74 H, CH₂Si), 1.30 (m, 30 H, CH₂CH₂CH₂ and SiCH₂CH₂CH₂N), 1.50-1.87 (m, 34 H, CH₂CH₂CH₂N), 2.65-2.85 (br. s, 24 H, CH₂NH₃⁺), 3.05 (m, 4 H, NCH₂CH₂N), 3.30-3.67 (br. s, 66 H, CH₂NH, C_{sp}CH₂N, CH₂CO and OCH₂), 4.24 (m, 2 H, CH₂NN), C_{sp}H not observed, 8.14 (br. s, 48 H, NH₃⁺), CONH not observed. The ¹³C NMR spectrum of this compound was not done due to the difficult to obtain a sufficient amount. Anal. Calc. for C₁₄₈H₃₄₈Cl₁₂N₂₂O₁₆Si₁₅ (3539.20): C, 50.23; H, 9.91; N, 8.71; Obt.: C, 50.01; H, 9.71; N, 8.62.

Z potential and size measurements. The particle size and zeta-potential of the complexes were measured using a Zetasizer Nano ZS (Malvern Instruments Ltd., UK) at 25 °C in a disposable Malvern plastic cuvette. The initial RNA concentration used was 250 nM. These samples were prepared and measured in 10 mmol/L Na-phosphate buffer, pH 7.4, which was filtered through 22 nm filter paper prior to use.

siRNA. All siRNA sequences were chosen from previously published results^{34,47,48} and had inhibited HIV replication in experiments using transiently transfected cells. They were purchased from Dharmacon. Inc. (Lafayette, CO). The sequence of the siRNA was siNEF sense: GUGCCUGGCUAGAAGCACAdTdT, antisense: UGUGCUUCUAGCCAGGCACdTdT. The siRNA siNEF labeled with the fluorochrome cyanine 3 (Cy3) on the 5' end of the sense strand was used to detect entry of siRNA into cells. In siRNA functionality experiments, a siRNA of random sequence was used as a negative control to test for sequence-specific effects (siRandom). This siRNA was siCONTROL Non-Targeting siRNA #2 and was designed and screened by Dharmacon to have no silencing effect on any human, mouse or rat genes.

Primary cell cultures. Blood samples were obtained from healthy anonymous donors from the transfusion centers of Albacete and Madrid, following national guidelines. Peripheral blood mononuclear cells (PBMC) were isolated on a Ficoll-Hypaque density gradient (Rafer, Spain) following the current procedures of the Spanish HIV HGM BioBank.⁴⁹ PBMC were activated with the mitogen phytohemagglutinin (PHA) (2μg/ml) and maintained in RPMI 1640 complete growth medium supplemented with 10% FBS and antibiotics along with interleukin-2 (20U/ml).

Dendriplex formation. Dendriplexes were formed by mixing equal volumes of dendrimer and siRNA dissolved in OPTIMEM® I free of serum or antibiotics at concentrations depending on the $-/+$ charge ratio and molar concentration desired.^{34,48} with an incubation time of 15 minutes.

Heparin exclusion experiments. These experiments were used to test the strength of the binding between dendrimer and siRNA. They were carried out by mixing dendriplexes ($-/+$ ratio 4) of **14**, ($-/+$ ratio 8) **15** or ($-/+$ ratio 2) **17** with varying concentrations of Heparin (0.1, 0.2, 0.3, and 0.6 U/ μ g siRNA). The mixture was run on a 2 % agarose gel, containing 1 μ l/ml of GelRed (Biotium), for 2 h at 90 V. The gels were photographed and the bands were quantified using the program ImageJ (1.38 \times , NIH, USA).

Cytotoxicity (MTT assay). PBMC were seeded in 96-well plates in OPTIMEM® I medium containing 10 % FBS (1.5×10^5 cells in 190 μ l/well) and submitted to 10 μ l treatment of siRNA alone or complexed with **14**, **15** or **17** at varying $-/+$ charge ratios. 20 h later, 20 μ l MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide) substrate solution (5mg/ml) was added to the cells to measure mitochondrial activity. After 4 h, the supernatant was removed and the crystals formed were dissolved in 200 μ l DMSO, and absorbance was measured at 550 nm with a reference of 690 nm. All points were performed in triplicate. Dextrane (5 μ M) and DMSO (15%) were used as positive and negative controls respectively.

HIV inhibition. PBMC stimulated with PHA for up to 72 h were infected with HIV NL4-3 at 0.05 or 0.01 MOI, respectively. The cells were washed twice with warm medium before being plated and treated with siRNA (250 nM) or dendriplexes at varying concentrations and $-/+$ charge ratios. The dendriplex treatment was applied to the infected cells within an hour of termination of the incubation with HIV. The dendriplex was formed in serum- and antibiotic-free OPTIMEM® I and incubated for 15 min at RT for the complex to form prior to its addition to the plated cells. Samples were collected every 24 h starting 24 h after treatment. They were then spun, and the supernatant was collected and assayed for viral concentration using the HIV protein p24 ELISA kit, following the manufacturer's instructions. The dilution factors depended on the MOI and the time point at which the sample was collected but ranged from 10^{-1} to 10^{-4} .

5. Acknowledgments.

This work has been supported by grants from the *Fondos de Investigación Sanitaria* (FIS) of the *Ministerio de Sanidad y Consumo* (PI061479), Red RIS RD06-0006-0035, FIPSE (24632/07), MNT-ERA NET 2007 (NAN2007-31198-E), the *Fundación Caja Navarra* and the *Comunidad de Madrid* (S-SAL-0159-2006) to M. A. M.-F.; the *Fondos de Investigación Sanitaria* (FIS) (PI080222), CTQ2011-23245, Consortium NANODENDMED ref S2011/BMD-2351 (CAM) to R. G; MICINN (CTQ2009-07758 and EUI2008-00174) and the *Generalitat de Catalunya* (2009SGR 1024) to F. A.; and MICINN (CTQ2008-00177) and MINECO (SAF2011- 30508-C02-01) to M. R. This study was also supported by CIBER-BBN as an initiative funded by the VI National R & D & i Plan 2008-2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions and financed by the *Instituto de Salud Carlos III*, with assistance from the European Regional Development Fund.

6. References

1. I. M. Verma and N. Somia, *Nature*, 1997, **389**, 239–242.
2. E. Wagner, *Mol. Ther.*, 2008, **16**, 1-2.
3. M. Cavazzana-Calvo and A. Fischer, *J. Clin. Invest.*, 2007, **117**, 1456–1465.
4. C. R. Dass, *J. Pharm. Pharmacol.*, 2002, **54**, 3-27.
5. K. Kodama, Y. Katayama, Y. Shoji and H. Nakashima, *Curr. Med. Chem.*, 2006, **13**, 2155-2161.
6. Z. Sideratou, L. A. Tziveleka, C. Kontoyianni, D. Tsiourvas and C. M. Paleos, *Gene Ther. Mol. Biol.*, 2006, **10A**, 71-94.
7. G. A. Pietersz, C. K. Tang and V. Apostolopoulos, *Mini-Rev. Med. Chem.*, 2006, **6**, 1285-1298.
8. M. Elfinger, S. Uezguen and C. Rudolph, *Curr. Nanosci.*, 2008, **4**, 322-353.
9. E. Fattal and A. Bochota, *Int. J. Pharm.*, 2008, **364**, 237-248.
10. M. A. Mintzer and E. E. Simanek, *Chem. Rev.*, 2009, **109**, 259-302.
11. X. Guo and L. Huang, *Acc. Chem. Res.*, 2012, **45**, 971–979.
12. J.-P. Behr, *Acc. Chem. Res.*, 2012, **45**, 980-984.
13. R. G. Denkewalter, J. F. Kolc and W. J. Lukasavage, *US Pat 4, 410, 688*, 1983.
14. R. G. Denkewalter, J. F. Kolc and W. J. Lukasavage, *US Pat 4, 360, 646*, 1982.
15. R. G. Denkewalter, J. F. Kolc and W. J. Lukasavage, *US Pat 4, 289, 872*, 1981.
16. F. Vögtle and C. A. Schalley, *Top. Curr. Chem.*, 2003, **228**.
17. G. R. Newkome, C. N. Moorefield and F. Vögtle, *Dendritic Molecules: Concepts, Syntheses, Perspectives*. VCH, Weinheim, Germany, 1996.
18. G. R. Newkome, C. N. Moorefield and F. Vögtle, *Dendrimers and Dendrons: Concepts, Syntheses, Applications*. Wiley-VCH, Weinheim, Germany., 2001.
19. G. R. Newkome and C. D. Shreiner, *Polymer*, 2008, **49**, 1-173.

20. D. A. Tomalia and J. M. J. Fréchet, *J. Polym. Sci., Part A: Pol. Chem.*, 2002, **40**, 2719-2728.
21. J. M. J. Fréchet and D. A. Tomalia, *Dendrimers and Other Dendritic Polymers VCH, Weinheim*, 2002.
22. D. Astruc, E. Boisselier and C. Ornelas, *Chem. Rev.*, 2010, **110**, 1857–1959.
23. X. Liu, P. Rocchi and L. Peng, *New J. Chem.*, 2012, **9**, 256-263.
24. P. M. H. Heegaard, U. Boas and N. S. Sorensen, *Bioconjugate Chem.*, 2010, **21**, 405-418.
25. D. G. Shcharbin, B. Klajnert and M. Bryszewska, *Biochemistry*, 2009, **74**, 1070-1079.
26. H. Zhong, Z. G. He, Z. Li, G. Y. Li, S. R. Shen and X. L. Li, *J. Biomater. Appl.*, 2008, **22**, 527-544.
27. D. K. Smith, *Curr. Top. Med. Chem.*, 2008, **8**, 1187-1203.
28. Y. Gao, G. Gao, Y. He, T. L. Liu and R. Qi, *Mini-Rev. Med. Chem.*, 2008, **8**, 889-900.
29. H. S. Parekh, *Curr. Pharm. Design*, 2007, **13**, 2837-2850.
30. M. Guillot-Nieckowski, S. Eisler and F. Diederich, *New J. Chem.*, 2007, **31**, 1111-1127.
31. C. Dufes, I. F. Uchegbu and A. G. Schatzlein, *Adv. Drug Delivery Rev.*, 2005, **57**, 2177-2202.
32. T. Gonzalo, M. I. Clemente, L. Chonco, N. D. Weber, L. Díaz, M. J. Serramía, R. Gras, P. Ortega, F. J. de la Mata, R. Gómez, L. A. López-Fernández, M. A. Muñoz-Fernández and J. L. Jiménez, *Chem. Med. Chem.*, 2010, **5**, 921–929.
33. I. Posadas, B. López-Hernández, M. I. Clemente, J. L. Jiménez, P. Ortega, F. J. de la Mata, R. Gómez, M. A. Muñoz-Fernández and V. Ceña, *Pharm. Res.*, 2009, **26**, 1181-1191.
34. N. Weber, P. Ortega, M. I. Clemente, D. Shcharbin, M. Bryszewska, F. J. de la Mata, R. Gómez and M. A. Muñoz-Fernández, *J. Control. Release*, 2008, **132**, 55-64.
35. J. F. Bermejo, P. Ortega, L. Chonco, R. Eritja, R. Samaniego, M. Mullner, E. de Jesús, F. J. de la Mata, J. C. Flores, R. Gómez and A. Muñoz-Fernández, *Chem. Eur. J.*, 2007, **13**, 483-495.
36. P. Ortega, J. F. Bermejo, L. Chonco, E. de Jesús, F. J. de la Mata, G. Fernández, J. C. Flores, R. Gómez, M. J. Serramía and M. A. Muñoz-Fernández, *Eur. J. Inorg. Chem.*, 2006, 1388-1396.
37. A. Sousa-Herves, R. Riguera and E. Fernández-Megía, *New J. Chem.*, 2012, **36**, 205-210.
38. H. Khambete, S. P. Gautam, C. Karthikeyan, S. Ramteke, N. S. H. N. Moorthy and P. Trivedi, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 4279–4281.
39. C. Kojima, C. Regino, Y. Umeda, H. Kobayashi and K. Kono, *Int. J. Pharm.*, 2010, **383**, 293–296.
40. S. J. Guillaudeu, M. E. Fox, Y. M. Haidar, E. E. Dy, F. C. Szoka and J. M. J. Fréchet, *Bioconjugate Chem.*, 2008, **19**, 461–469.
41. J. Lim, Y. Guo, C. L. Rostollan, J. Stanfield, J.-T. Hsieh, X. Sun and E. E. Simanek, *Mol. Pharm.*, 2008, **5**, 540–547.
42. T. Takahashi, J. Hirose, C. Kojima, A. Harada and K. Kono, *Bioconjugate Chem.*, 2007, **18**, 1163-1169.
43. T.-I. Kim, H. J. Seo, J. S. Choi, H.-S. Jang, J.-U. Baek, K. Kim and J.-S. Park, *Biomacromolecules*, 2004, **5**, 2487-2492.
44. D. Luo, K. Haverstick, N. Belcheva, E. Han and W. M. Saltzman, *Macromolecules*, 2002, **35**, 3456-3462.
45. J. Sánchez-Nieves, P. Ortega, M. A. Muñoz-Fernández, R. Gómez and F. J. de la Mata, *Tetrahedron*, 2010, 9203-9213.
46. N. de las Cuevas, S. García-Gallego, B. Rasines, F. J. de la Mata, L. G. Guijarro, M. Á. Muñoz-Fernández and R. Gómez, *Curr. Med. Chem.*, 2012, **19**, 5052-5061.
47. A. T. Das, T. R. Brummelkamp, E. M. Westerhout, M. Vink, M. Madiredjo, R. Bernards and B. Berkhout, *J. Virol.*, 2004, **78**, 2601–2605.
48. J. L. Jiménez, M. I. Clemente, N. D. Weber, J. Sánchez, P. Ortega, F. J. de la Mata, R. Gómez, D. García, L. A. López-Fernández and M. A. Muñoz-Fernández, *BioDrugs*, 2010, **24**, 331-343.
49. I. García-Merino, N. d. L. Cuevas, J. L. Jiménez, J. Gallego, C. Gómez, C. Prieto, M. J. Serramía, R. Lorente and M. Á. Muñoz-Fernández, *Retrovirology*, 2009, **6**, 27.

For Table of Contents:

Amphiphilic Cationic Carbosilane-PEG Dendrimers: Synthesis and Applications in Gene Therapy

Javier Sánchez-Nieves,^{a,b} Peter Fransen,^c Daniel Pulido,^{b,d} Raquel Lorente,^e M. Ángeles Muñoz-Fernández,^{b,e} Fernando Albericio,^{b,c,f,} Miriam Royo,^{b,d,*} Rafael Gómez^{a,b,*} and F. Javier de la Mata^{a,b,*}*

Cationic amphiphilic dendrimers

^a Department of Química Orgánica y Química Inorgánica, Universidad de Alcalá, Campus Universitario, E-28871 Alcalá de Henares (Madrid) Spain. FAX: 00 34 91 885 4683; Phone: 00 34 91 885 4685.

^b Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN).


^c Institute for Research in Biomedicine, Barcelona Science Park, Baldiri Reixac 10, 08028 Barcelona, Spain.

^d Combinatorial Chemistry Unit, Barcelona Science Park, Baldiri Reixac 10, 08028 Barcelona, Spain

^e Laboratorio de Inmunología Molecular, Hospital General Universitario Gregorio Marañón, Madrid (Spain).

^f Department of Organic Chemistry, University of Barcelona, Martí i Franqués 1-11, 08028 Barcelona, Spain

Cationic ammonium Janus-type dendrimers have been synthesized via click chemistry coupling of carbosilane (generation 1 to 3) and PEG-based dendrons functionalized at the focal point with azide and alkyne moieties, respectively. These amphiphilic dendrimers have been studied as vectors for gene therapy against HIV in peripheral blood mononuclear cells (PBMC) and the results have been compared with a homocarbosilane dendrimer, observing the positive influence of the PEG unit.



Keywords: dendrimers, click chemistry, carbosilane, PEG, gene therapy, HIV.